Resveratrol Reverses Menopausal Depression by Rebuilding Brain Synapses

Depression during menopause affects millions of women yet remains poorly understood at the neurobiological level, and existing treatments carry significant side effects. Identifying natural compounds that can safely address this condition is a high priority in translational neuroscience.

This study constructed a menopausal depression model by combining surgical ovariectomy with chronic restraint stress in transgenic mice. The transgenic strain expressed yellow fluorescent protein specifically in excitatory neurons, enabling high-resolution 3D imaging of dendritic structures. Resveratrol was then administered to assess its antidepressant potential.

Across four behavioral tests — the tail suspension test, forced swimming test, sucrose preference test, and novel inhibitory feeding test — resveratrol-treated mice showed meaningful reductions in depression-like behaviors. Critically, these behavioral improvements were accompanied by measurable biological changes: elevated BDNF mRNA in the hippocampus and medial prefrontal cortex, increased phosphorylation of cofilin1, and greater density of dendritic spines on excitatory neurons in both regions.

Cofilin1 is an actin-regulatory protein whose phosphorylation stabilizes the actin cytoskeleton within dendritic spines, promoting spine growth and synaptic strength. By upregulating BDNF and enhancing cofilin1 phosphorylation, resveratrol appears to physically restore synaptic connectivity that is degraded by estrogen loss and chronic stress — offering a mechanistic explanation for its antidepressant effect.

While promising, the study is limited to a mouse model, and translation to human menopausal depression requires clinical validation. Nonetheless, these findings add mechanistic depth to the growing literature on resveratrol's neuroprotective properties and highlight synaptic remodeling via BDNF-cofilin1 signaling as a viable therapeutic target.